SUSCEPTIBILITY OF NRTI-RESISTANT HIV-2 ISOLATES TO A NEW NRTI, GS-9131
Management of HIV-2 infection is hampered by the limited number of active ARV drugs and the rapid acquisition of drug resistance-associated mutations (DRAMs). There is still a strong need for new ARV effective on HIV-2, especially for patients infected by multi-drug resistant viruses. GS-9131 is the prodrug of GS-9148, a new NRTI with low potential…